Today In Biotech: Gilead Sciences (GILD), MannKind Corporation (MNKD), EnteroMedics (ETRM), Synergy Pharmaceuticals (SGYP)

Gilead Sciences Is Climbing Today: Will It Last?

Gilead Sciences, Inc. (NASDAQ: GILD)

Gilead Sciences is having an incredible day in the market as I predicted in yesterday’s post on the stock. The reality is that while the entire market declined Friday and Monday, GILD is so undervalued at the moment that it’s not likely to hold losses. Gilead Sciences currently maintains control over the HCV market and maintains a PE ratio well below 10; that’s a match made in heaven. Currently (2:26), GILD is trading at $105.78 per share after a gain of 5.09% so far today. Considering everything I’ve found in my research, there’s no reason not to expect more gains out of the stock moving forward. So, moving forward, this one is a great stock to watch for opportunities.

MannKind Corporation Continues Declines: Bulls Still Aren’t Concerned

MannKind Corporation (NASDAQ: MNKD)

MannKind Corporation is seeing a continuation of declines today. It seems as though short interest is just too heavy on the stock and hindering a recovery. Nonetheless, MNKD has quite a bit coming down the lines that is likely to push the value of the stock up in a big way. First and foremost, Afrezza is finally getting positive reactions from insurance companies. Beyond that the Direct to Consumer phase is headed down the lines along with approval from Europe and Asia. Another factor that people don’t seem to be talking about is the fact that MNKD is taking advantage of its proprietary technology to come up with new treatments that are likely coming down the road in the field of pain management. All in all, MNKD is a great stock going through rough times. However, rough times cause discounted prices. So, I believe that there’s plenty of opportunity here as well.

EnteroMedics Is Having A Strong Day In The Market

EnteroMedics Inc (NASDAQ: ETRM)

EnteroMedics is having a great day in the market today. Not only is the stock recovering from the declines we saw in the last two trading sessions, it is gaining on good news with regard to commercialization of vBlock. As a result, Canaccord analyst, William Plovanic, recently weighed in on the stock, rating it a “Buy” and offering a price target of $2.50. Here’s what the analyst had to say

We are encouraged by the initial commercialization progress with 51 centers certified and 77 surgeons trained on the procedure. These metrics are tracking ahead of management guidance and other expectations which called for 30 certified sites by YE2015 previously. Additionally, EnteroMedics provided color regarding its DTC campaigns and educational Webinars to drive patients to vBlock Therapy. Lastly, EnteroMedics has expanded access to the procedure through financing options and reimbursement support.”

In Other news, Dr. Knudson, ETRM’s founder, CEO, President and Chairman will be retiring effective December 31st, 2015. He will maintain his seat as Chairman of the board and continue to play a vital role in the company. Currently (2:40), ETRM is trading at $0.26 per share after a gain of 15.12% so far today.

Synergy Pharmaceuticals Edges Higher

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP)

Finally, Synergy Pharmaceuticals is edging up in the market today as well, working to recover from the losses we saw Friday and Monday. However, I don’t think the big climb is happening now. In fact, in December, we are likely to see momentous movement as the company submits its first NDA with the FDA. Currently (2:43), SGYP is trading at $6.80 per share after a gain of 0.89%. To find out more about what I’m expecting to see moving forward, click here.

Image Credit

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!
* indicates required

Add Comment